JNJ-1493 / J&J, Xencor - LARVOL DELTA

A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=130 | Recruiting | Sponsor: Janssen Research & Development, LLC | N=80 ➔ 130 | Not yet recruiting ➔ Recruiting

Enrollment change • Enrollment open • First-in-human • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer (clinicaltrials.gov) - P1 | N=70 | Active, not recruiting | Sponsor: Janssen Research & Development, LLC | Recruiting ➔ Active, not recruiting | N=235 ➔ 70 | Trial completion date: Nov 2027 ➔ Aug 2026 | Trial primary completion date: Nov 2027 ➔ Jan 2026

Enrollment change • Enrollment closed • First-in-human • Trial completion date • Trial primary completion date • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

JNJ-87801493 (CD20xCD28), a Potential First-in-Class CD20 Targeted CD28 Costimulatory Bispecific Antibody, Enhances the Activity of B-Cell Targeting T-Cell Engagers in Preclinical Models (ASH 2024) - P1 | "In conclusion, our data establishes the preclinical activity of JNJ-87801493 and its impact on the in vitro and in vivo efficacy of TCEs through improved T-cell function. A clinical trial (NCT06139406) is underway to characterize the safety and clinical activity of JNJ-87801493 in combination with JNJ-80948543 in participants with previously treated B-cell NHL."

Preclinical • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20 • CD79B • CD80 • CD86

A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer (clinicaltrials.gov) - P1 | N=235 | Recruiting | Sponsor: Janssen Research & Development, LLC | Trial primary completion date: Jul 2026 ➔ Nov 2027

Trial primary completion date • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer (clinicaltrials.gov) - P1 | N=235 | Recruiting | Sponsor: Janssen Research & Development, LLC | N=70 ➔ 235 | Trial completion date: Jul 2026 ➔ Nov 2027

Enrollment change • Trial completion date • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Xencor Regains CD20 x CD3 Bispecific T-Cell Engager (Businesswire) - "Xencor, Inc...announced it will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, which Xencor advanced through Phase 1 clinical development in hematologic cancers. In 2021, Xencor entered a collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize plamotamab and novel B-cell targeting bispecific antibodies designed to conditionally activate T cells through the CD28 co-stimulatory receptor....Xencor has been notified that Janssen will terminate its rights to plamotamab under the collaboration and license agreement. Janssen has retained its rights to develop and commercialize B-cell targeting CD28 bispecific antibodies, including JNJ-9401 (PSMA x CD28) and JNJ-1493 (CD20 x CD28)."

Licensing / partnership • Hematological Malignancies • Leukemia • Lymphoma • Metastatic Castration-Resistant Prostate Cancer • Non-Hodgkin’s Lymphoma • Oncology • Prostate Cancer • Solid Tumor

A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer (clinicaltrials.gov) - P1 | N=70 | Recruiting | Sponsor: Janssen Research & Development, LLC | Not yet recruiting ➔ Recruiting | Trial completion date: Jul 2028 ➔ Jul 2026

Combination therapy • Enrollment open • Trial completion date • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology